Adagrasib

Adagrasib
Clinical data
Trade names	Krazati
Other names	MRTX-849
AHFS/Drugs.com	Monograph
MedlinePlus	a623003
License data	US DailyMed: Adagrasib;
Routes of; administration	By mouth
Drug class	Antineoplastic agent
ATC code	L01XX77 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name {(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1methylpyrrolidin-2-yl]methoxy}-5,6,7,8tetrahydropyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop2-enoyl)piperazin-2-yl}acetonitrile;
CAS Number	2326521-71-3;
PubChem CID	138611145;
DrugBank	DB15568;
UNII	8EOO6HQF8Y;
KEGG	D12301;
CompTox Dashboard (EPA)	DTXSID801336759 ;
ECHA InfoCard	100.329.928
Chemical and physical data
Formula	C32H35ClFN7O2
Molar mass	604.13 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F;
	InChI InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1; Key:PEMUGDMSUDYLHU-ZEQRLZLVSA-N;

Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer. Adagrasib is an inhibitor of G12C mutated KRAS GTPase. It is taken by mouth. It is being developed by Mirati Therapeutics.

The most common adverse reactions include diarrhea, nausea, fatigue, vomiting, musculoskeletal pain, hepatotoxicity, renal impairment, dyspnea, edema, decreased appetite, cough, pneumonia, dizziness, constipation, abdominal pain, and QTc interval prolongation. The most common laboratory abnormalities include decreased lymphocytes, increased aspartate aminotransferase, decreased sodium, decreased hemoglobin, increased creatinine, decreased albumin, increased alanine aminotransferase, increased lipase, decreased platelets, decreased magnesium, and decreased potassium.

It was approved for medical use in the United States in December 2022 for lung cancer and together with Cetuximab in 2024 for colorectal cancer.